Skip to main content
Figure 1 | Cancer Cell International

Figure 1

From: CDK2-AP1 inhibits growth of breast cancer cells by regulating cell cycle and increasing docetaxel sensitivity in vivo and in vitro

Figure 1

Expression of CDK2-AP1 is reduced successively in normal breast tissue, DCIS, invasive breast cancer and relapsed breast cancer, contrary to CDK2 and CyclinD1. A, The positive rates of CDK2-AP1 in normal breast tissue, DCIS, invasive breast cancer and relapsed breast cancer were 72.5, 16.7, 14.0 and 5.6%, respectively. Accordingly the positive rates of CDK2 and CyclinD1 were 7.5, 40.0, 52.1and 55.6%; and 12.5, 50.0, 55.4 and 50%. B, Positive staining of CDK2-AP1 (×200) C, Positive staining of CDK2-AP1 (×200, in the nucleoli).

Back to article page